The backend infrastructure built by compound pharmacies to serve telehealth giants like Hims and Ro is now mature. This creates an opportunity for new brands to quickly launch and ship prescription products, effectively using these pharmacies as a platform for regulated health and wellness DTC.

The high cost of insulin isn't from manufacturing but from the complex distribution chain of wholesalers, pharmacies, and insurers. Project Insulin's core strategy is to bypass this system entirely with a direct-to-patient mail-order pharmacy model, effectively eliminating the middlemen who inflate the final price.

The US healthcare system rewards inefficiency, with multiple parties adding costs. Cash-pay systems bypass this, offering services and drugs at a lower net price by avoiding negotiations and markups inherent in the insurance-based model.

Major pharmacy chains like Walgreens and CVS are abandoning their clinical trial businesses after realizing the operational costs and complexities were far greater than anticipated. This failure suggests the decentralized trial model may be better suited for nimble, independent pharmacies rather than large retail giants.

The emergence of low-cost, compounded versions of GLP-1 drugs from telehealth companies like Hims is creating significant pricing pressure on market leaders Novo Nordisk and Eli Lilly. This dynamic has pushed the pharma giants toward direct-to-consumer models with lower prices to compete.

Walgreens prioritizes tackling barriers to medication access—such as cost and prior authorizations—believing that adherence can only be addressed once a patient can consistently obtain their therapy. This frames the two issues as a sequence, not parallel challenges.

According to a dermatologist CEO, patients seeking prescriptions online via telehealth are a distinct cohort from those visiting a doctor's office. The typical in-clinic patient first tries over-the-counter products, not telehealth solutions, suggesting these channels serve different consumer journeys and largely separate market segments.

Direct-to-consumer telehealth companies like Hims achieve rapid growth via a vertically integrated model of marketing, medical groups, and pharmacies. This structure allows them to generate revenue from selling medicines, a more scalable business than relying on fees from the practice of medicine alone.

Life sciences companies risk obsolescence not from direct competitors, but from the tech and wellness industries. These sectors are capitalizing on patient empowerment and consumerization, innovating in ways the traditional healthcare industry has not, thereby filling the void and capturing patient trust.